Study guide
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction
Key Takeaways Explain This Topic AI
Neutropenic sepsis is a neutrophil count of 0.5 x 10^9/L or lower with a temperature above 38 degrees Celsius or signs of sepsis, and demands empirical broad-spectrum antibiotics within one hour.
Suspected metastatic spinal cord compression requires whole-spine MRI within 24 hours plus immediate dexamethasone 16 mg daily with proton pump inhibitor cover.
Superior vena cava obstruction causes facial swelling, distended non-pulsatile neck veins and Pemberton sign, and is most often caused by lung cancer or lymphoma.
Last updated: October 2026
Oncological emergencies represent acute, potentially life-threatening clinical conditions that develop directly from malignant disease or secondary to antineoplastic therapy. Rapid recognition, immediate physiological stabilization, and guideline-directed emergency pharmacotherapy are core competencies frequently tested in the MRCP(UK) Part 1 examination.
- 1. Neutropenic Sepsis
- Clinical Definition & Risk Stratification
According to UK National Institute for Health and Care Excellence (NICE CG151) guidelines, neutropenic sepsis is defined as:
An absolute neutrophil count (ANC) < 0.5 × 10⁹/L , OR an ANC expected to fall below 0.5 × 10⁹/L within 48 hours;
AND either a temperature > 38.0 °C OR symptoms/signs consistent with clinically significant sepsis (hypotension, tachycardia, tachypnoea, rigors, altered mental status, or localized tissue infection), regardless of body temperature (elderly or immunocompromised patients may be hypothermic).
The nadir for neutrophil suppression characteristically occurs 7 to 14 days following cytotoxic chemotherapy (particularly with intensive anthracycline-, taxane-, and platinum-based regimens).
Emergency Protocol: The "Door-to-Needle" One-Hour Rule
Neutropenic sepsis is a medical emergency with a mortality rate exceeding 20% if antimicrobial therapy is delayed. The door-to-needle time must not exceed 1 hour from initial clinical presentation:
Do NOT wait for laboratory confirmation: Broad-spectrum intravenous antipseudomonal antibiotics must be administered immediately upon clinical suspicion. Do NOT delay administration to obtain a full blood count, wait for blood culture bottles to arrive, or await central line swab results.
Diagnostic Sampling (Simultaneous with or immediately preceding antibiotics):
Blood cultures: Mandatory paired cultures—one set drawn from a peripheral vein and separate sets drawn from each lumen of every indwelling central venous catheter (e.g. Hickman, PICC, Port-a-Cath).
Serum lactate, full blood count, urea and electrolytes, liver function tests, C-reactive protein, and coagulation screen.
Urinalysis and culture, sputum culture, chest radiograph, and stool testing for Clostridioides difficile toxin if diarrhoea is present.
Important Exam Negative: Digital rectal examination (DRE) is strictly contraindicated in neutropenic patients due to the risk of mucosal trauma and introducing enteric flora into the systemic circulation, precipitating fatal polymicrobial sepsis.
Empirical Antimicrobial Regimens
First-Line Monotherapy: Intravenous piperacillin-tazobactam (Tazocin) 4.5 g every 6 hours (or 4.5 g every 8 hours depending on renal function).
Severe Penicillin Allergy (Anaphylaxis, Angioedema, Bronchospasm): Intravenous meropenem 1 g every 8 hours (carbapenems provide robust Pseudomonas aeruginosa coverage and broad-spectrum anaerobic/Gram-negative efficacy). Alternatively, intravenous aztreonam plus vancomycin or ciprofloxacin plus vancomycin.
Specific Add-On Indications:
Suspected Central Venous Catheter Infection or MRSA Colonisation: Add intravenous vancomycin (or teicoplanin).
Septic Shock / Severe Haemodynamic Instability: Add an intravenous aminoglycoside (e.g. gentamicin or amikacin) for synergistic Gram-negative coverage.
Suspected Invasive Fungal Infection: If fever persists beyond 72–96 hours despite broad-spectrum antibacterials, initiate empirical antifungal therapy (e.g. liposomal amphotericin B or voriconazole/caspofungin).
Granulocyte Colony-Stimulating Factor (G-CSF)
Recombinant G-CSF (Filgrastim, Pegfilgrastim): Stimulates neutrophil proliferation, differentiation, and survival in the bone marrow.
Primary Prophylaxis: Indicated when the anticipated risk of febrile neutropenia for a given chemotherapy regimen exceeds 20%, administered 24–72 hours post-chemotherapy completion.
Secondary Prophylaxis: Given in subsequent cycles if the patient experienced febrile neutropenia in a prior cycle without dose reduction.
Therapeutic G-CSF in Established Neutropenic Sepsis: NOT routinely recommended for all patients. Reserved strictly for patients with established sepsis who have high-risk adverse prognostic features: profound shock, multi-organ dysfunction, pneumonia, invasive fungal sepsis, or absolute neutrophil count < 0.1 × 10⁹/L with anticipated prolonged myelosuppression.
- 2. Metastatic Spinal Cord Compression (MSCC)
- Epidemiology & Anatomical Distribution
Metastatic spinal cord compression affects 5–10% of all cancer patients and represents an oncological and neurosurgical emergency. Irreversible paraplegia ensues within hours to days if compressive ischemia is untreated.
Commonest Primary Malignancies:
- Prostate carcinoma (most common in males);
- Breast carcinoma (most common in females);
- Lung carcinoma (small cell and non-small cell);
- Renal cell carcinoma ;
Multiple myeloma and lymphoma.
Anatomical Levels:
Thoracic spine (60–70%): Most frequent due to the large number of vertebral bodies and narrow spinal canal.
Lumbosacral spine (20–30%): Compresses the conus medullaris or cauda equina.
Cervical spine (10%): High risk of quadriplegia and respiratory compromise.
Clinical Presentation & Red Flag Symptoms
Spinal Pain (Earliest Sign, >90% of cases):
Severe, unremitting, progressive localized back pain, typically preceding neurological deficits by weeks.
Worse on lying flat (due to distension of the epidural venous plexus) and waking the patient at night.
Exacerbated by straining, coughing, sneezing, or movement.
Radicular "Band-Like" Pain: Sensation of a tight band wrapping circumferentially around the chest or abdomen (thoracic root compression).
Motor Dysfunction: Progressive symmetrical or asymmetrical lower-extremity weakness; difficulty climbing stairs or standing from a chair; upper motor neuron signs (spasticity, brisk patellar/Achilles reflexes, clonus, extensor/upgoing plantar responses).
Sensory Deficits: Sensation of walking on cotton wool, ascending paraesthesias, and a well-demarcated sensory level corresponding to the anatomical cord lesion (e.g. T4 at nipples, T10 at umbilicus).
Autonomic / Sphincter Disturbance (Late & Ominous Sign): Urinary hesitancy progressing to painless urinary retention with overflow incontinence ; constipation and loss of anal sphincter tone. Sphincter loss indicates severe, often irreversible neurological injury.
Emergency Investigation Algorithm
Gold Standard: Urgent contrast-enhanced whole-spine MRI (sagittal and axial T1, T2, and STIR sequences) .
Timeline Mandate: Must be performed within 24 hours of presentation if MSCC is clinically suspected, and immediately within 6 hours if progressive motor weakness or neurological signs are already established.
Whole-Spine Requirement: Imaging the entire spine is mandatory because 20–30% of patients have multiple non-contiguous spinal metastases that dictate surgical and radiation portals.
Emergency Management Protocol
Corticosteroids (Immediate): Administer oral dexamethasone 16 mg daily (either 16 mg as a single morning dose or 8 mg twice daily with meals) co-prescribed with a proton pump inhibitor (PPI, e.g. omeprazole 20 mg daily) for gastroprotection. Dexamethasone rapidly reduces vasogenic spinal cord oedema and improves microvascular perfusion.
Immobilisation & Nursing Care: Strict bed rest with flat spine precautions and log-rolling until spinal mechanical stability is confirmed by the neurosurgical/spinal team.
Definitive Treatment Consultation: Immediate contact with the regional MSCC Coordinator / Spinal Surgery / Clinical Oncology:
Surgical Decompression & Posterior Fixation (Patchell Criteria): First-line for patients with single-level cord compression, mechanical spinal instability, bony fragment retropulsion, unknown primary histology, radioresistant tumours (renal cell, melanoma), and neurological deficit duration < 48 hours in patients with an expected survival > 3 months.
External Beam Radiotherapy (EBRT): Primary treatment for radiosensitive tumours (myeloma, lymphoma, small cell lung cancer), multilevel disease, non-ambulatory patients with prolonged paraplegia (>48 hours), or patients unfit for surgical intervention.
- 3. Superior Vena Cava (SVC) Obstruction
- Pathophysiology & Etiology
The superior vena cava is a thin-walled, low-pressure vascular vessel situated in the middle/anterior mediastinum, encircled by rigid nodal stations and the trachea. Extrinsic compression, direct transmural invasion, or secondary intraluminal thrombosis causes obstruction to venous drainage from the head, neck, and upper extremities.
Malignant Causes (>85% of cases):
Small cell lung cancer (SCLC): ~40% (rapidly growing, central mediastinal mass).
Non-small cell lung cancer (NSCLC): ~40% (squamous cell, adenocarcinoma).
Non-Hodgkin lymphoma: ~10–15% (particularly diffuse large B-cell and lymphoblastic lymphoma in young adults).
Metastatic disease (germ cell tumours, breast adenocarcinoma, thymoma).
Non-Malignant Causes (<15%): Thrombosis secondary to indwelling central venous lines, pacemakers, or mediastinal fibrosis.
Clinical Presentation
Facial Oedema & Plethoric Suffusion: Facial fullness, puffy eyelids, conjunctival chemosis/suffusion, and periorbital oedema, classically pronounced in the morning upon waking.
Venous Distension: Markedly engorged, non-pulsatile neck veins and extensive subcutaneous collateral venous networks over the anterior chest and abdominal wall.
Pemberton's Sign: Elevation of both arms above the head for 1 minute induces marked facial congestion, cyanosis, and inspiratory stridor due to increased intrathoracic pressure and thoracic inlet crowding.
Respiratory & Neurological Symptoms: Dyspnoea (most common symptom), orthopnoea, cough, hoarseness (recurrent laryngeal nerve compression), stridor (indicates life-threatening laryngeal oedema requiring emergent intubation), headache, dizziness, and visual blurring (cerebral venous hypertension).
Investigation & Emergency Management
Investigation: Contrast-enhanced CT thorax with intravenous contrast is the diagnostic investigation of choice, defining the level of venous occlusion, collateral pathways, presence of intraluminal thrombus, and underlying parenchymal/nodal mass.
Medical Management:
Elevate the head of the bed to 45° to enhance gravitational venous drainage.
Administer high-dose oral dexamethasone 16 mg daily with PPI cover (rapidly reduces peritumoral inflammation and laryngeal oedema).
Definitive Treatment:
Endovascular SVC Stenting: The definitive treatment of choice for rapid symptom relief, providing dramatic clinical improvement in 80–90% of patients within 24–48 hours, irrespective of underlying histology.
Urgent Systemic Chemotherapy: Indicated for highly chemosensitive malignancies (SCLC, lymphoma, germ cell tumours).
Urgent Radiotherapy: Indicated for radioresponsive malignancies (NSCLC) where stenting is unavailable or contraindicated.
Anticoagulation: Full therapeutic anticoagulation (low molecular weight heparin or DOAC) if intraluminal thrombus is demonstrated.